Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Does RAGE protect smokers from COPD?

R.P. Young, B.A. Hay, R.J. Hopkins
European Respiratory Journal 2011 38: 743-744; DOI: 10.1183/09031936.00041711
R.P. Young
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: roberty@adhb.govt.nz
B.A. Hay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R.J. Hopkins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

We read with interest the article by Smith et al. [1], which showed a positive correlation between plasma soluble receptor for advanced glycation end-products (sRAGE) and forced expiratory volume in 1 s (FEV1) in patients with chronic obstructive pulmonary disease (COPD). Here, we outline the results of recent genetic epidemiological studies that suggest the advanced glycosylation end product-specific receptor (AGER) gene, which encodes sRAGE, may also have a role in the development of COPD.

Two recent large genome-wide association (GWA) studies conclude that a locus on chromosome 6p21 is associated with lung function (FEV1 and FEV1/forced vital capacity) [2, 3], directly implicating the AGER gene, which is known to be expressed in alveolar epithelial cells [2]. However, this association was made in populations dominated by nonsmokers and did not specifically examine the effect in chronic smokers. We and others have proposed that COPD results from the combined effect of chronic smoking exposure and the presence or absence of a variable combination of protective and susceptible genetic variants [4, 5]. In this regard, we have examined the same AGER variant (single-nucleotide polymorphism (SNP)) reported in the GWA studies (rs2070600) in 484 smokers with normal lung function (“resistant” smokers) and 455 matched smokers with COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage ≥2 on pre-bronchodilator spirometry). We found that the minor allele (T allele or CT/TT genotype) of the AGER SNP was more frequently found in resistant smokers compared with those with COPD (15 versus 10%; OR 0.60, 95% CI 0.40–0.91; p = 0.01) [6]. The T allele of this SNP converts glycine to serine at position 82 in the third exon encoding the sRAGE protein (a nonsynonymous change altering polarity at this position) and has been shown to be associated with both reduced serum sRAGE levels and increased sRAGE signalling compared with the more common C allele [1]. This change in sRAGE signalling affects downstream gene expression through mitogen-activated protein kinases and nuclear factor-κB, both of which have been implicated in the inflammatory response in COPD.

Collectively, these studies suggest that the AGER gene (encoding sRAGE) may play a role in the development of COPD. sRAGE has systemic anti-inflammatory activity that may have relevance in lung tissue, which is both highly vascular and extensively exposed to various pro-inflammatory aeropollutant insults [1]. Smoking is the most well-known of these aeropollutant exposures and also the most easily quantified, albeit retrospectively. This makes COPD an excellent model with which to examine gene–environment interactions in order to identify genetic variants conferring either protective or susceptibility effects. That COPD is associated with low plasma levels of a ubiquitous systemic anti-inflammatory mediator like sRAGE [1] is somewhat analogous to α1-antitrypsin deficiency. It is also consistent with the findings that, when compared with resistant smokers, smokers with COPD less frequently carry other SNP variants implicated in pulmonary–systemic anti-oxidant/anti-inflammatory activity (e.g. extracellular superoxide dismutase (SOD3), protective effect [4]; Hedgehog-interacting protein (HHIP), protective effect 6; and the family with sequence familiarity 13 member A (FAM13A), protective effect [6]). These findings suggest that SNPs conferring a resistant (protective) effect maybe just as (or even more) important as susceptible SNPs.

Such an observation has major implications in the genetics of smoking-related lung disease, where exposure to smoking may result in quite different outcomes due to the genetic makeup of the person exposed. First, this is very relevant to study design, as prospective epidemiological studies show 60–70% of chronic smokers maintain normal or near-normal lung function (adjusted FEV1) despite decades of smoking [7], while the remainder develop COPD of variable severity. In contrast with light smokers or nonsmokers, where the distribution of adjusted FEV1 is normal, chronic smokers show a trimodal FEV1 distribution consistent with a moderating genetic effect [8]. Therefore, recruitment of unaffected (resistant) smokers is as important as the recruitment of smokers with COPD to correctly assign smokers as resistant or susceptible. Secondly, if the mechanisms underlying the protective genetic effects can be better understood, then drugs simulating these protective effects (e.g. statins [9, 10]) may help prevent the development of COPD. While further genetic studies will be required to establish the functional variant(s) underlying the association of AGER with COPD, further discovery of novel pathogenetic pathways underlying responsiveness to smoking exposure (and development of COPD) are likely to emerge through well-designed genetic epidemiological studies.

Footnotes

  • Statement of Interest

    Statements of interest for R.P. Young and R.J. Hopkins can be found at www.erj.ersjournals.com/site/misc/statements.xhtml

  • ©ERS 2011

REFERENCES

  1. ↵
    1. Smith DJ,
    2. Yerkovich ST,
    3. Towers MA,
    4. et al
    . Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J 2011; 37: 516–522.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Repapi E,
    2. Sayers I,
    3. Wain LV,
    4. et al
    . Genome-wide association study identifies five loci associated with lung function. Nat Genet 2009; 42: 36–44.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Hancock DB,
    2. Eijgelsheim M,
    3. Wilk JB,
    4. et al
    . Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet 2009; 42: 45–52.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Young RP,
    2. Hopkins R,
    3. Black PN,
    4. et al
    . Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function. Thorax 2006; 61: 394–399.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Molfino NA
    . Genetics of COPD. Chest 2004; 125: 1929–1940.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Young RP,
    2. Hopkins RJ,
    3. Whittington CF,
    4. et al
    . Individual and cumulative effects of GWAS susceptibility loci in lung cancer: associations after sub-phenotyping for COPD. PLoS One 2011; 6: e16476.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Løkke A,
    2. Lange P,
    3. Scharling H,
    4. et al
    . Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935–939.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Young RP,
    2. Hopkins RJ,
    3. Eaton TE
    . Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J 2007; 30: 616–622.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Mahajan N,
    2. Bahl A,
    3. Dhawan V
    . C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int J Cardiol 2010; 142: 273–278.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Young RP,
    2. Hopkins R,
    3. Eaton TE
    . Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 2009; 18: 222–232.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 38 Issue 3 Table of Contents
European Respiratory Journal: 38 (3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Does RAGE protect smokers from COPD?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Does RAGE protect smokers from COPD?
R.P. Young, B.A. Hay, R.J. Hopkins
European Respiratory Journal Sep 2011, 38 (3) 743-744; DOI: 10.1183/09031936.00041711

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Does RAGE protect smokers from COPD?
R.P. Young, B.A. Hay, R.J. Hopkins
European Respiratory Journal Sep 2011, 38 (3) 743-744; DOI: 10.1183/09031936.00041711
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Treatable traits approach in interstitial lung disease
  • Reply: Treatable traits approach in interstitial lung disease
  • Reply: TB screening in migrants to the EU/EEA and UK
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society